The FDA gave emergency authorization for 12-15-year-olds to receive the COVID vaccine.
In the FDA press release, no clinical trials are cited.
They cite data out of Israel.
MORE – The Pfizer "booster" injection for children in the U.S. receives emergency authorization on the basis of "real-world" data from Israel. No clinical trials are cited in the FDA press release.
— Disclose.tv (@disclosetv) January 3, 2022
The Food and Drug Administration expanded COVID-19 vaccine booster eligibility on Monday to allow 12- to 15-year-olds to receive a third shot of the Pfizer-BioNTech vaccine.
This comes after a study found that Pfizer’s booster shot is more likely to give young men under 40 heart inflammation.
Males under 40 years old are more likely to experience heart inflammation after getting a booster shot of Pfizer’s COVID-19 vaccine than COVID-19 itself, according to a recently published study.
Males in the age group had a myocarditis incidence rate ratio of 7.6 in the 28 days following receipt of a Pfizer booster, researchers with the University of Oxford and other UK institutions found.
That was higher than the ratio of 2 in the four weeks following a positive COVID-19 test result.
“For the first time, we observe an increase in myocarditis events following a third dose of BNT162b vaccine,” researchers wrote in their study, which has not been peer reviewed as of yet.
The Palmieri Report is a Pro-America News Outlet founded by Jacob Palmieri. The Palmieri Report is dedicated to giving people the truth so that they can form their own informed political opinions. You can help us beat Big Tech by following us on GETTR , Telegram, and Rumble.
Listen to our Daily News Podcast!